AIM:To examine the association between the single nucleotide polymorphisms (SNPs)of matrix metalloprotease-9 (MMP-9) gene and primary angleclosure glaucoma(PACG)in a Chinese Han population.METHODS:DNA samples were ext...AIM:To examine the association between the single nucleotide polymorphisms (SNPs)of matrix metalloprotease-9 (MMP-9) gene and primary angleclosure glaucoma(PACG)in a Chinese Han population.METHODS:DNA samples were extracted from peripheral-blood mononuclear cells of 214 PACG patients and 224 healthy controls.Genotyping of rs3918249,rs3918254,rs17577 and rs3787268 in MMP-9was performed using polymerase chain reaction restriction fragment length polymorphism(PCR-RFLP)analysis and the direct sequencing technique.The association between these genetic polymorphisms and risk of PACG was estimated by χ2 test.RESULTS:The distributions of rs3918249,rs3918254,rs17577 and rs3787268 genotypes among cases and healthy controls were compatible with that from HardyWeinberg equilibrium(HWE,P>0.05).The increased frequency of CC and CT genotypes of rs3918254 were observed in PACG patients compared to healthy controls[P=0.006,P corrected(Pcorr)=0.048].The haplotype analysis showed that the CCGG haplotype was nominal associated with PACG(P=0.015),however,the significant was lost when the Bonferroni correction was used(Pcorr=0.105).CONCLUSION:Our results revealed that rs3918254 in MMP-9 may be a susceptible locus to PACG in China,people with the CC and CT genotypes of rs3918254 are more susceptible to PACG.The susceptibility to PACG inChinese Han patients may be not influenced by SNPs rs3918249,rs3787268 and rs17577 in MMP-9.展开更多
At present,there are no resto rative therapies in the clinic for spinal cord injury,with current treatments offering only palliative treatment options.The role of matrix metalloproteases is well established in spinal ...At present,there are no resto rative therapies in the clinic for spinal cord injury,with current treatments offering only palliative treatment options.The role of matrix metalloproteases is well established in spinal cord injury,howeve r,translation into the clinical space was plagued by early designs of matrix metalloprotease inhibitors that lacked specificity and fears of musculos keletal syndrome prevented their further development.Newe r,much more specific matrix metalloprotease inhibitors have revived the possibility of using these inhibitors in the clinic since they are much more specific to their to rget matrix metalloproteases.Here,the evidence for use of matrix metalloproteases after spinal cord injury is reviewed and researche rs are urged to overcome their old fears rega rding matrix metalloprotease inhibition and possible side effects for the field to progress.Recently published work by us shows that inhibition of specific matrix metalloproteases after spinal cord injury holds promise since four key consequences of spinal cord injury could be alleviated by specific,next-gene ration matrix metalloprotease inhibitors.For example,specific inhibition of matrix metalloprotease-9 and matrix metalloprotease-12 within 24 hours after injury and for 3 days,alleviates spinal cord injury-induced edema,blood-s pinal co rd barrier breakdown,neuro pathic pain and resto res sensory and locomotor function.Attempts are now underway to translate this therapy into the clinic.展开更多
基金Supported by National Natural Science Foundation of China(No.81270990No.81070723)
文摘AIM:To examine the association between the single nucleotide polymorphisms (SNPs)of matrix metalloprotease-9 (MMP-9) gene and primary angleclosure glaucoma(PACG)in a Chinese Han population.METHODS:DNA samples were extracted from peripheral-blood mononuclear cells of 214 PACG patients and 224 healthy controls.Genotyping of rs3918249,rs3918254,rs17577 and rs3787268 in MMP-9was performed using polymerase chain reaction restriction fragment length polymorphism(PCR-RFLP)analysis and the direct sequencing technique.The association between these genetic polymorphisms and risk of PACG was estimated by χ2 test.RESULTS:The distributions of rs3918249,rs3918254,rs17577 and rs3787268 genotypes among cases and healthy controls were compatible with that from HardyWeinberg equilibrium(HWE,P>0.05).The increased frequency of CC and CT genotypes of rs3918254 were observed in PACG patients compared to healthy controls[P=0.006,P corrected(Pcorr)=0.048].The haplotype analysis showed that the CCGG haplotype was nominal associated with PACG(P=0.015),however,the significant was lost when the Bonferroni correction was used(Pcorr=0.105).CONCLUSION:Our results revealed that rs3918254 in MMP-9 may be a susceptible locus to PACG in China,people with the CC and CT genotypes of rs3918254 are more susceptible to PACG.The susceptibility to PACG inChinese Han patients may be not influenced by SNPs rs3918249,rs3787268 and rs17577 in MMP-9.
文摘At present,there are no resto rative therapies in the clinic for spinal cord injury,with current treatments offering only palliative treatment options.The role of matrix metalloproteases is well established in spinal cord injury,howeve r,translation into the clinical space was plagued by early designs of matrix metalloprotease inhibitors that lacked specificity and fears of musculos keletal syndrome prevented their further development.Newe r,much more specific matrix metalloprotease inhibitors have revived the possibility of using these inhibitors in the clinic since they are much more specific to their to rget matrix metalloproteases.Here,the evidence for use of matrix metalloproteases after spinal cord injury is reviewed and researche rs are urged to overcome their old fears rega rding matrix metalloprotease inhibition and possible side effects for the field to progress.Recently published work by us shows that inhibition of specific matrix metalloproteases after spinal cord injury holds promise since four key consequences of spinal cord injury could be alleviated by specific,next-gene ration matrix metalloprotease inhibitors.For example,specific inhibition of matrix metalloprotease-9 and matrix metalloprotease-12 within 24 hours after injury and for 3 days,alleviates spinal cord injury-induced edema,blood-s pinal co rd barrier breakdown,neuro pathic pain and resto res sensory and locomotor function.Attempts are now underway to translate this therapy into the clinic.
